InSitu Biologics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-08-10.
InSitu Biologics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on August 10, 2026. The filing reports $1.25M sold. Its industry group is Biotechnology. It names Daniel Halpern (Executive Officer, Director), Bill Taylor (Executive Officer), Sandi Klemann (Executive Officer) (SEC Form D/A, August 10, 2026).
In its own words: “InSitu Biologics is advancing localized sustained-release drug delivery, starting with INSB200™, a peripheral nerve block for extended post-surgical pain relief.” (insitubiologics.com, checked November 1, 2026)
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to InSitu Biologics, Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like InSitu Biologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns InSitu Biologics, Inc.
Free to see. No signup.
More on the people and the money behind InSitu Biologics, Inc., from the filings we hold.
Biotechnology raises by companies based in Minnesota, filed within 90 days of this one, largest first.
Get an email when InSitu Biologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when InSitu Biologics, Inc. raises, hires or launches. No email unless you switch it on.
Watch InSitu Biologics, Inc. →Get the full cited report on InSitu Biologics, Inc.
What the filing shows about InSitu Biologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on InSitu Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives InSitu Biologics, Inc.'s address as 3510 Hopkins Place N., Building 4, Oakdale, MN 55128.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for InSitu Biologics, Inc. →
Amended on 2026-10-14: the offering size changed from $2,500,000 to $3,375,000. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
InSitu Biologics, Inc. is a registered filer with the SEC (CIK 1723443) and has filed since 2023-12-29. 3 filings are on record, the latest on 2026-08-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
InSitu Biologics, Inc.'s Form D of 2026-08-10 names Daniel Halpern, Bill Taylor, Sandi Klemann and 3 more as its officers, directors or promoters.
Its new offerings report $8.20M sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $1.25M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Excludes ordinary course compensation paid to officers.
Checked away from the filing. What is below does not come from the record on sec.gov.
InSitu Biologics is advancing localized sustained-release drug delivery, starting with INSB200™, a peripheral nerve block for extended post-surgical pain relief.
The title and description the site itself served, answering 200, after redirecting from https://insitubiologics.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Daniel Halpern is named as Executive Officer and Director on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
Bill Taylor is named as Executive Officer on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
Sandi Klemann is named as Executive Officer on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
Robert Wilson is named as Director on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
Greg Van Guilder is named as Director on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
Ivan Shaw is named as Director on the Form D that InSitu Biologics, Inc. filed with the SEC on 10 August 2026, one of 6 people that filing names.
6 people named on the filing — 3 holding an executive role and 3 as directors only.
Named as of the 2026-08-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about InSitu Biologics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on InSitu Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InSitu Biologics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist InSitu Biologics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind InSitu Biologics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (insitubiologics.com).
Each opens in a new tab, filled in for InSitu Biologics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-08-10 · Biotech raises, week of 2026-08-10
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/insitu-biologics-inc-form-d-26000001